Literature DB >> 28990708

Astroblastoma: a distinct tumor entity characterized by alterations of the X chromosome and MN1 rearrangement.

Takanori Hirose1,2, Sumihito Nobusawa3, Kazuhiko Sugiyama4, Vishwa J Amatya5, Naomi Fujimoto6, Atsushi Sasaki7, Yoshiki Mikami8, Akiyoshi Kakita9, Shinya Tanaka10, Hideaki Yokoo3.   

Abstract

Astroblastoma is a rare, enigmatic tumor of the central nervous system (CNS) which shares some clinicopathologic aspects with other CNS tumors, especially ependymoma. To further clarify the nature of astroblastoma, we performed clinicopathologic and molecular genetic studies on eight cases of astroblastoma. The median age of the patients was 14.5 years, ranging from 5 to 60 years, and seven of the patients were female. All tumors arose in the cerebral hemisphere and radiologically appeared to be well-bordered, nodular tumors often associated with cystic areas and contrast-enhancement. Six of the seven patients with prognosis data survived without recurrences during the follow-up periods ranging from six to 76 months. One patient had multiple recurrences and died six years later. All tumors exhibited salient microscopic features, such as being well demarcated from the surrounding brain tissue, perivascular arrangement of epithelioid tumor cells (represented by "astroblastic" pseudorosettes, trabecular alignment, and pseudopapillary patterns), and hyalinized blood vessels. Immunoreactivity for GFAP, S-100 protein, Olig2, and EMA was variably demonstrated in all tumors, and IDH1 R132H and L1CAM were negative. Array comparative genomic hybridization revealed numerous heterozygous deletions on chromosome X in the four tumors studied, and break-apart fluorescence in situ hybridization demonstrated rearrangement of MN1 in five tumors with successful testing. The characteristic clinicopathologic and genetic findings support the idea that astroblastoma is distinct from other CNS tumors, in particular, ependymoma. In addition, MN1 rearrangement and aberrations of chromosome X may partly be involved in the pathogenesis of astroblastoma.
© 2017 International Society of Neuropathology.

Entities:  

Keywords:  MN1; astroblastoma; chromosome X

Mesh:

Substances:

Year:  2017        PMID: 28990708     DOI: 10.1111/bpa.12565

Source DB:  PubMed          Journal:  Brain Pathol        ISSN: 1015-6305            Impact factor:   6.508


  9 in total

1.  Molecular Profiling Reclassifies Adult Astroblastoma into Known and Clinically Distinct Tumor Entities with Frequent Mitogen-Activated Protein Kinase Pathway Alterations.

Authors:  William Boisseau; Philipp Euskirchen; Karima Mokhtari; Caroline Dehais; Mehdi Touat; Khê Hoang-Xuan; Marc Sanson; Laurent Capelle; Aurélien Nouet; Carine Karachi; Franck Bielle; Justine Guégan; Yannick Marie; Nadine Martin-Duverneuil; Luc Taillandier; Audrey Rousseau; Jean-Yves Delattre; Ahmed Idbaih
Journal:  Oncologist       Date:  2019-07-25

Review 2.  The 2021 World Health Organization Classification of Tumors of the Central Nervous System: What Neuroradiologists Need to Know.

Authors:  A G Osborn; D N Louis; T Y Poussaint; L L Linscott; K L Salzman
Journal:  AJNR Am J Neuroradiol       Date:  2022-06-16       Impact factor: 4.966

3.  Recurrence- and Malignant Progression-Associated Biomarkers in Low-Grade Gliomas and Their Roles in Immunotherapy.

Authors:  Chubei Teng; Yongwei Zhu; Yueshuo Li; Luohuan Dai; Zhouyang Pan; Siyi Wanggou; Xuejun Li
Journal:  Front Immunol       Date:  2022-05-23       Impact factor: 8.786

Review 4.  A pediatric cerebral tumor with MN1 alteration and pathological features mimicking carcinoma metastasis: may the terminology "high grade neuroepithelial tumor with MN1 alteration" still be relevant?

Authors:  Ramazan Sari; Meric A Altinoz; Enis Ozyar; Ayca Ersen Danyeli; Ilhan Elmaci
Journal:  Childs Nerv Syst       Date:  2021-07-16       Impact factor: 1.475

Review 5.  Molecular Classification and Management of Rare Pediatric Embryonal Brain Tumors.

Authors:  Patrick Sin-Chan; Bryan K Li; Ben Ho; Adriana Fonseca; Annie Huang
Journal:  Curr Oncol Rep       Date:  2018-07-11       Impact factor: 5.075

6.  Identification of novel SSX1 fusions in synovial sarcoma.

Authors:  Akihiko Yoshida; Yasuhito Arai; Kaishi Satomi; Takashi Kubo; Eijitsu Ryo; Yuko Matsushita; Natsuko Hama; Kazuki Sudo; Motokiyo Komiyama; Yasushi Yatabe; Tatsuhiro Shibata; Hitoshi Ichikawa; Koichi Ichimura; Akira Kawai; Taisuke Mori
Journal:  Mod Pathol       Date:  2021-09-09       Impact factor: 7.842

7.  Genomic analysis demonstrates that histologically-defined astroblastomas are molecularly heterogeneous and that tumors with MN1 rearrangement exhibit the most favorable prognosis.

Authors:  Norman L Lehman; Aisulu Usubalieva; Tong Lin; Sariah J Allen; Quynh T Tran; Bret C Mobley; Roger E McLendon; Matthew J Schniederjan; Maria-Magdalena Georgescu; Marta Couce; Mohanpal S Dulai; Jack M Raisanen; Mousa Al Abbadi; Cheryl A Palmer; Eyas M Hattab; Brent A Orr
Journal:  Acta Neuropathol Commun       Date:  2019-03-15       Impact factor: 7.801

8.  Spinal cord astroblastoma with EWSR1-BEND2 fusion classified as HGNET-MN1 by methylation classification: a case report.

Authors:  Takeyoshi Tsutsui; Yoshiki Arakawa; Yasuhide Makino; Hiroharu Kataoka; Yohei Mineharu; Kentaro Naito; Sachiko Minamiguchi; Takanori Hirose; Sumihito Nobusawa; Yoshiko Nakano; Koichi Ichimura; Hironori Haga; Susumu Miyamoto
Journal:  Brain Tumor Pathol       Date:  2021-07-27       Impact factor: 3.298

9.  Ependymoma-like tumor with mesenchymal differentiation harboring C11orf95-NCOA1/2 or -RELA fusion: A hitherto unclassified tumor related to ependymoma.

Authors:  Ran Tomomasa; Yasuhito Arai; Reika Kawabata-Iwakawa; Kohei Fukuoka; Yoshiko Nakano; Natsuko Hama; Satoshi Nakata; Nozomi Suzuki; Yukitomo Ishi; Shinya Tanaka; Jun A Takahashi; Yoshiaki Yuba; Mitsutaka Shiota; Atsushi Natsume; Michihiro Kurimoto; Yoshiki Shiba; Mikiko Aoki; Kazuki Nabeshima; Toshiyuki Enomoto; Tooru Inoue; Junya Fujimura; Akihide Kondo; Takashi Yao; Naoki Okura; Takanori Hirose; Atsushi Sasaki; Masahiko Nishiyama; Koichi Ichimura; Tatsuhiro Shibata; Junko Hirato; Hideaki Yokoo; Sumihito Nobusawa
Journal:  Brain Pathol       Date:  2021-02-12       Impact factor: 6.508

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.